Overview
Nolvadex is classified as a PCT (post-cycle therapy) and ancillary compound. Selective estrogen receptor modulator.
With a half-life of ~14 days (336 hours), Nolvadex supports less frequent dosing schedules. Taken orally, it has a bioavailability of approximately 95% via its primary route.
Half-life approximately 14 days. Active metabolite endoxifen has an even longer elimination half-life. One-compartment model.
Mechanism of Action
Nolvadex's pharmacological activity involves the following key pathways:
Selective Estrogen Receptor Modulation
Nolvadex acts as a selective estrogen receptor modulator, functioning as an antagonist in breast tissue while having varying effects in other estrogen-sensitive tissues.
Hypothalamic Feedback
By blocking estrogen receptors in the hypothalamus, Nolvadex interrupts negative feedback, which can stimulate endogenous gonadotropin production.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
5 mg/day
Route
Oral
Frequency
Every 10-14 days
Duration
4-8 weeks
Dose
30 mg/day
Route
Oral
Frequency
Every 10-14 days
Duration
4-8 weeks
Frequently Asked Questions
What is Tamoxifen (Nolvadex) and how does it work for PCT?
Tamoxifen (Nolvadex) is a selective estrogen receptor modulator (SERM) that blocks estrogen from binding to receptors in breast tissue and the hypothalamus. By occupying estrogen receptors in the hypothalamus and pituitary gland, it removes the negative feedback loop that suppresses gonadotropin release, leading to increased production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This cascade signals the testes to resume natural testosterone production, making it one of the most widely used post-cycle therapy compounds.
What is the half-life of Tamoxifen and how long does it stay in your system?
Tamoxifen has a biphasic elimination with a terminal half-life of approximately 5–7 days (120–168 hours). Its primary active metabolite, N-desmethyl tamoxifen, has an even longer half-life of approximately 14 days. Steady-state plasma concentrations of tamoxifen are typically reached in about 4 weeks, while N-desmethyl tamoxifen reaches steady state in approximately 8 weeks. After discontinuation, tamoxifen and its metabolites remain detectable in the circulation for at least 6 weeks.
What is the standard Tamoxifen PCT dosage and protocol?
The most commonly observed PCT protocol is 40 mg per day for the first 2 weeks, followed by 20 mg per day for the remaining 2 weeks, totaling a 4-week course. For milder cycles, a lower-dose protocol of 20 mg per day for 3 weeks followed by 10 mg per day for 1 week is also frequently reported. PCT timing depends on the compounds used — it is typically started approximately 2 weeks after the last injection of a long-acting ester, or 1–2 days after the final dose of a short-acting oral compound.
Does Tamoxifen affect SHBG and free testosterone levels?
Tamoxifen acts as an estrogen agonist in the liver, which has been observed to increase sex hormone-binding globulin (SHBG) levels by approximately 20%. While tamoxifen raises total testosterone through LH/FSH stimulation, the concurrent SHBG increase binds more circulating testosterone, which can reduce free (bioavailable) testosterone. Tamoxifen has also been observed to reduce IGF-1 levels by approximately 25%. These effects are dose-dependent and are a key consideration when comparing tamoxifen to other SERM options for PCT.
What side effects are commonly reported with Tamoxifen in men?
The most commonly reported side effects in men include hot flashes, reduced libido, and mood changes. Visual disturbances — including retinal deposits and changes in visual acuity — have been observed in a small percentage of users, particularly with prolonged use. Tamoxifen is metabolized primarily through the CYP2D6 enzyme pathway, meaning individuals who are poor metabolizers may experience different side effect profiles. Most side effects are dose-dependent and resolve after discontinuation.
How does Tamoxifen compare to Clomid and Enclomiphene for PCT?
All three are SERMs that stimulate LH and FSH production, but they differ in key ways. Tamoxifen is the most extensively studied and has decades of clinical data behind it. However, it raises SHBG more than alternatives, which can reduce free testosterone despite increasing total testosterone. Clomiphene (Clomid) contains both anti-estrogenic and estrogenic isomers, with the estrogenic component (zuclomiphene) accumulating over time. Enclomiphene — the isolated anti-estrogenic isomer — has been observed to produce fewer side effects while maintaining comparable testosterone elevation. The choice between them often depends on individual response and availability.